Dr Jie Tang

Advance QLD Research Fellow

Australian Institute for Bioengineering and Nanotechnology
j.tang3@uq.edu.au
+61 7 334 63823

Overview

Research Interests

  • Nanomaterials-based Cancer therapy and immunotherapy
    By understanding the complicated tumor micro-environment, I am developing innovative materials (e.g., openwork@dendritic mesoporous silica nanoparticles, disulfide-bond-incorporated mesoporous organosilica nanoparticles, and ultra-small nanochelators, tumour targeting lipid calcium phosphate nanoparticles) and strategies (e.g., lactate depletion, immunogenic cell death improvement, bioavailable copper depletion, and photothermal therapy combined with gene therapy) for advanced cancer therapy and immunotherapy.
  • Engineering biomimetic nanoplatform for oral delivery
    Development of novel biomimetic drug delivery platform based on nanoparticles with engineered morphology/architecture, micicking gut microbes to achieve enhanced mucus penetration and transcytosis through intestinal epithelium.
  • Nanotechnology for Livestock Healthcare
    1. Developing a safe and efficient (antibiotic-free anti-bacterial nano-formulation) to supplement animal nutrition products; 2. Engineering nano-digestive enzymes to address small animal digestive problems. Core technology patented and licensed to Ridley limited corporation (Australia’s leading animal nutrition provider) who expanded the application of this technology as antigen delivery system in animal feed additives for infection control (currently trialed on chicken). In collaboration with Darwalla and Ridley, Dr Tang has been awarded an AQIRF ($360000) grant to carry on nanoadjuvants research from 2020.
  • Nanoadjuvants development
    By combining state-of-the-art nanotechnology and classical coordination chemistry, we develop new generation aluminosilicate nanoadjuvants with improved efficacy and safety over current market Alum-based adjuvants (which do not activate cellular mediated immunity). The core technology is being patented with industrial partner who has launched ‘NUVEC’, an adjuvant delivery system for cancer vaccines.

Qualifications

  • Doctor of Philosophy, The University of Queensland
  • Master of Science, Sichuan University

Publications

View all Publications

Grants

View all Grants

Supervision

  • Doctor Philosophy

  • Doctor Philosophy

  • (2022) Doctor Philosophy

View all Supervision

Publications

Journal Article

Other Outputs

Grants (Administered at UQ)

PhD and MPhil Supervision

Current Supervision

  • Doctor Philosophy — Principal Advisor

    Other advisors:

  • Doctor Philosophy — Associate Advisor

    Other advisors:

  • Doctor Philosophy — Associate Advisor

    Other advisors:

  • Doctor Philosophy — Associate Advisor

    Other advisors:

Completed Supervision

  • (2022) Doctor Philosophy — Associate Advisor

  • (2020) Master Philosophy — Associate Advisor

    Other advisors: